BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR BEMCENTINIB FROM TWO PHASE II COVID-19 STUDIES AT ECCMID
· Survival 96.6% vs 91.2% · Significantly reduced likelihood (69%) of progression to ventilation in higher severity cohort · Significantly increased likelihood (88%) of shorter time to recovery or discharge in higher severity cohort · Clinical evidence of anti-viral mechanism of action · Preclinical analysis highlights bemcentinib’s potential against COVID-19 variants Bergen, Norway, 12 July 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, has presented a combined